Carcinomas from three patients (Patients E, O and P), including a patient with homozygous frameshift mutation in BRCA2 (Patient P), had relatively low HRD scores (< 10) and low genome-wide LOH burden (<0.10). This evidence concerns the gene BRCA2 and carcinoma.